These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 26125270)

  • 1. YM155 inhibits tumor growth and enhances chemosensitivity to cisplatin in osteosarcoma.
    Gao JZ; Chen FH; Wang L; Wei H; Meng SL
    Eur Rev Med Pharmacol Sci; 2015; 19(11):2062-9. PubMed ID: 26125270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Silencing of survivin using YM155 induces apoptosis and chemosensitization in neuroblastomas cells.
    Liang H; Zhang L; Xu R; Ju XL
    Eur Rev Med Pharmacol Sci; 2013 Nov; 17(21):2909-15. PubMed ID: 24254560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models.
    Yamanaka K; Nakahara T; Yamauchi T; Kita A; Takeuchi M; Kiyonaga F; Kaneko N; Sasamata M
    Clin Cancer Res; 2011 Aug; 17(16):5423-31. PubMed ID: 21737502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of YM155, a selective survivin suppressant, in combination with cisplatin in hepatoblastoma.
    Yu Y; Zhao X; Zhang Y; Kang Y; Wang J; Liu Y
    Oncol Rep; 2015 Jul; 34(1):407-14. PubMed ID: 25955434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survivin selective inhibitor YM155 promotes cisplatin‑induced apoptosis in embryonal rhabdomyosarcoma.
    Ueno T; Uehara S; Nakahata K; Okuyama H
    Int J Oncol; 2016 May; 48(5):1847-54. PubMed ID: 26983495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model.
    Nakahara T; Yamanaka K; Hatakeyama S; Kita A; Takeuchi M; Kinoyama I; Matsuhisa A; Nakano K; Shishido T; Koutoku H; Sasamata M
    Anticancer Drugs; 2011 Jun; 22(5):454-62. PubMed ID: 21389848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. YM155 sensitizes ovarian cancer cells to cisplatin inducing apoptosis and tumor regression.
    Mir R; Stanzani E; Martinez-Soler F; Villanueva A; Vidal A; Condom E; Ponce J; Gil J; Tortosa A; Giménez-Bonafé P
    Gynecol Oncol; 2014 Jan; 132(1):211-20. PubMed ID: 24262875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual induction of apoptotic and autophagic cell death by targeting survivin in head neck squamous cell carcinoma.
    Zhang L; Zhang W; Wang YF; Liu B; Zhang WF; Zhao YF; Kulkarni AB; Sun ZJ
    Cell Death Dis; 2015 May; 6(5):e1771. PubMed ID: 26018732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. YM155 reverses cisplatin resistance in head and neck cancer by decreasing cytoplasmic survivin levels.
    Kumar B; Yadav A; Lang JC; Cipolla MJ; Schmitt AC; Arradaza N; Teknos TN; Kumar P
    Mol Cancer Ther; 2012 Sep; 11(9):1988-98. PubMed ID: 22723337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of YM155, a survivin suppressant, with bendamustine and rituximab: a new combination therapy to treat relapsed/refractory diffuse large B-cell lymphoma.
    Kaneko N; Mitsuoka K; Amino N; Yamanaka K; Kita A; Mori M; Miyoshi S; Kuromitsu S
    Clin Cancer Res; 2014 Apr; 20(7):1814-22. PubMed ID: 24486595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small Molecule Survivin Inhibitor YM155 Displays Potent Activity Against Human Osteosarcoma Cells.
    Zhang S; Wang X; Gu Z; Wang L
    Cancer Invest; 2016 Sep; 34(8):401-7. PubMed ID: 27559851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancer.
    Yamanaka K; Nakata M; Kaneko N; Fushiki H; Kita A; Nakahara T; Koutoku H; Sasamata M
    Int J Oncol; 2011 Sep; 39(3):569-75. PubMed ID: 21674125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survivin inhibitor YM155 suppresses gastric cancer xenograft growth in mice without affecting normal tissues.
    Cheng XJ; Lin JC; Ding YF; Zhu L; Ye J; Tu SP
    Oncotarget; 2016 Feb; 7(6):7096-109. PubMed ID: 26771139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor effect of YM155, a novel small-molecule survivin suppressant, via mitochondrial apoptosis in human MFH/UPS.
    Minoda M; Kawamoto T; Ueha T; Kamata E; Morishita M; Harada R; Toda M; Onishi Y; Hara H; Kurosaka M; Akisue T
    Int J Oncol; 2015 Sep; 47(3):891-9. PubMed ID: 26166250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. YM155 exerts a growth inhibitory effect on human osteosarcoma in vitro and in vivo.
    Zhang Z; Ma L; Wang J
    Oncol Rep; 2015 Aug; 34(2):1074-80. PubMed ID: 26081496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. YM155 Down-Regulates Survivin and Induces P53 Up-Regulated Modulator of Apoptosis (PUMA)-Dependent in Oral Squamous Cell Carcinoma Cells.
    Yan X; Su H
    Med Sci Monit; 2017 Apr; 23():1963-1972. PubMed ID: 28435150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The survivin suppressant YM155 potentiates chemosensitivity to gemcitabine in the human pancreatic cancer cell line MiaPaCa-2.
    Yoon DH; Shin JS; Jin DH; Hong SW; Jung KA; Kim SM; Hong YS; Kim KP; Lee JL; Suh C; Lee JS; Kim TW
    Anticancer Res; 2012 May; 32(5):1681-8. PubMed ID: 22593446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. YM155 reverses rapamycin resistance in renal cancer by decreasing survivin.
    Koike H; Nitta T; Sekine Y; Arai S; Furuya Y; Nomura M; Matsui H; Shibata Y; Ito K; Oyama T; Suzuki K
    J Cancer Res Clin Oncol; 2014 Oct; 140(10):1705-13. PubMed ID: 24916171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. YM155 enhances the cytotoxic activity of etoposide against canine osteosarcoma cells.
    Ong SM; Saeki K; Kok MK; Nakagawa T; Nishimura R
    J Vet Med Sci; 2019 Aug; 81(8):1182-1190. PubMed ID: 31308291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. YM155 Reverses Statin Resistance in Renal Cancer by Reducing Expression of Survivin.
    Nitta T; Koike H; Miyao T; Miyazawa Y; Kato H; Furuya Y; Sekine Y; Suzuki K
    Anticancer Res; 2017 Jan; 37(1):75-80. PubMed ID: 28011476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.